Medelis, Inc., a prominent player in the clinical research industry, is headquartered in the United States and operates across key regions globally. Founded in 2005, the company has established itself as a leader in providing comprehensive clinical trial services, particularly in oncology and rare diseases. Medelis is renowned for its innovative approach to clinical development, offering unique solutions that streamline the trial process and enhance patient engagement. With a strong focus on quality and efficiency, the company has achieved significant milestones, including successful collaborations with major pharmaceutical firms. Recognised for its expertise and commitment to advancing medical research, Medelis continues to solidify its market position, making substantial contributions to the development of life-saving therapies.
How does Medelis, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Medelis, Inc.'s score of 28 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Medelis, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary of Altasciences Company, Inc., any climate commitments or emissions data may be influenced by the parent company's initiatives. However, no specific reduction targets or climate pledges have been documented for Medelis, Inc. at this time. Given the absence of direct emissions data, it is important to note that Medelis, Inc. may align with broader industry standards and practices regarding carbon emissions and climate commitments, potentially inheriting strategies from Altasciences Company, Inc. as part of their corporate family relationship. As the company continues to develop its sustainability strategies, stakeholders can anticipate future disclosures that may include specific emissions metrics and reduction targets.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Medelis, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.